Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMOU1PK)

• Drug Name: Praziquantel Drug Info
• Synonyms: Azinox; Biliricide; Biltricide; Cesol; Cisticid; Cutter; Cysticide; Droncit; Drontsit; Prasiquantel; Praziquantelum; Pyquiton; Traziquantel; Bayer Brand of Praziquantel; Cutter Tape Tabs; Merck Brand of Praziquantel; Embay 8440; P 4668; Bay-8440; Biltricide (TN); EMBAY-8440; NPFAPI-02; Praziquantelum [INN-Latin]; Biltricide, Droncit, Praziquantel; Praziquantel (JAN/USP/INN); Praziquantel [USAN:INN:BAN:JAN]; Praziquantel, (R)-Isomer; Praziquantel, (S)-Isomer; Praziquantel, (+-)-Isomer; (+-)-2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1a)isoquinolin-4-one; (11bS)-2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a)isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]-isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazino(2,1a)isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazinoe(2,1a)isoquinolin-4-one; 2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one; 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; 2-Cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one; 2-Cyclohexylcarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a) isoquinolin-4-one; 8440, EMBAY
• Therapeutic Class: Anthelmintics
• Cross-matching ID:
  PubChem CID: 4891
  ChEBI ID: CHEMBL976
  CAS Number: CAS 55268-74-1
  TTD Drug ID: D0L9ZR
  INTEDE Drug ID: DR1329
  ACDINA Drug ID: D00549

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Melanogenesis	2.14	0.00e+0	74/101 (73.27%)	GNAI1;PRKCB;CALML5;...
Circadian entrainment	1.99	2.31e-2	85/97 (87.63%)	GNAI1;GUCY1A1;PRKCB;...
Long-term depression	1.96	2.31e-2	55/60 (91.67%)	GNAI1;GUCY1A1;PRKCB;...
Progesterone-mediated oocyte maturation	1.94	1.73e-2	75/100 (75%)	GNAI1;CCNA2;CCNB1;...
Gap junction	1.93	1.39e-2	72/88 (81.82%)	GNAI1;GUCY1A1;PRKCB;...
DNA replication	1.86	2.31e-2	34/36 (94.44%)	MCM6;MCM2;PRIM1;...
Oocyte meiosis	1.84	2.15e-2	90/129 (69.77%)	CALML5;CCNB1;CDC20;...
Morphine addiction	1.83	1.88e-2	80/91 (87.91%)	GNAI1;PRKCB;PRKCA;...
Renin secretion	1.78	1.93e-2	61/69 (88.41%)	GNAI1;GUCY1A1;CALML5;...
Growth hormone synthesis, secretion and action	1.78	1.97e-2	108/119 (90.76%)	GNAI1;PRKCB;SST;...
Cell cycle	1.76	2.52e-2	110/124 (88.71%)	CCNA2;CCNB1;CDC20;...
GABAergic synapse	1.75	2.50e-2	76/89 (85.39%)	GNAI1;PRKCB;PRKCA;...
Vascular smooth muscle contraction	1.72	3.20e-2	113/133 (84.96%)	ADM;GUCY1A1;PRKCB;...
Human immunodeficiency virus 1 infection	1.70	3.39e-2	189/212 (89.15%)	GNAI1;PRKCB;CALML5;...
Inflammatory mediator regulation of TRP channels	1.69	3.31e-2	82/98 (83.67%)	PRKCB;CALML5;PTGER4;...
Cholinergic synapse	1.69	3.54e-2	99/113 (87.61%)	GNAI1;PRKCB;PRKCA;...
Glucagon signaling pathway	1.69	3.40e-2	89/107 (83.18%)	PFKP;CALML5;PFKL;...
Gastric acid secretion	1.66	4.17e-2	63/76 (82.89%)	GNAI1;PRKCB;CALML5;...
Platelet activation	1.64	4.62e-2	106/124 (85.48%)	GNAI1;GUCY1A1;SRC;...
Caffeine metabolism	-1.70	4.29e-2	5/6 (83.33%)	NAT1;CYP1A2
Nicotinate and nicotinamide metabolism	-1.71	4.42e-2	25/35 (71.43%)	NMRK2;QPRT;SIRT5;...
NF-kappa B signaling pathway	-1.73	4.60e-2	90/104 (86.54%)	CXCL3;EDA2R;TNFSF11;...
Staphylococcus aureus infection	-1.80	2.72e-2	72/95 (75.79%)	FPR1;FGG;KRT31;...
ECM-receptor interaction	-1.83	1.95e-2	80/88 (90.91%)	ITGB4;ITGA3;LAMC3;...
Other glycan degradation	-2.00	4.18e-3	13/18 (72.22%)	GLB1;NEU2;MANBA;...
Complement and coagulation cascades	-2.71	0.00e+0	76/85 (89.41%)	SERPINB2;A2M;CD59;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H	Hide ▲

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	10uM	72H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼